Collection and Analysis of the Clinical and Biological Characteristics of Patients Treated for Giant Cells ARTEitis (Horton's Disease) (CARTECEL)

Centre Hospitalier Universitaire de Nīmes

Status: Completed

Conditions: Giant Cell Arteritis; Horton Disease

Treatments: Other: no intervention

Study type: Observational

Funder types: Other

Identifiers

NCT04142515

Local2019/RG-01

Details and patient eligibility

About

Giant cell arteritis (GCA) or Horton's disease: frequent large vessel vasculitis (cephalic) (incidence estimated at 9 per 100,000 in France), potentially responsible for blindness.

Treatment: corticosteroid therapy, which is effective in the vast majority of cases.

Clinical problem: relapse; 36% to 44% of patients have a relapse that occurs in the first year for many patients, requiring a re-escalation of corticosteroid therapy, with its consequences:

• Cumulative dose of corticosteroid therapy that causes cardiovascular and infectious morbidity.
• Requires additional immunosuppressive treatment.

Enrollment: 83 patients

Sex: All

Ages: 45+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients aged 45 years or older
• Patients with giant cell arteritis according to ACR criteria or revised criteria incorporating imaging parameters,
• Patients managed at the University Hospital of Carémeau in Internal Medicine from 01/01/2011 to 01/01/2020.

Exclusion criteria

None